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Background/aim: The purpose of the study was to cross-culturally adapt the Multiple Sclerosis Impact Scale-29 (MSIS-29) into Turkish
and evaluate its reliability and validity in patients with Multiple Sclerosis (MS).
Materials and methods: A total of 119 individuals with MS were enrolled in the research. The neurologist classified the patients with
Expanded Disability Status Scale (EDSS). In the initial evaluation, patients completed the Multiple Sclerosis Impact Scale-29 (MSIS29), the Multiple Sclerosis International Quality of Life (MusiQoL), EuroQol-5D-3L (EQ-5D-3L), and Beck Depression Scale (BDS),
respectively one week later, the MSIS-29 evaluation was repeated. Internal consistency, test-retest reliability, and construct validity were
assessed, separately.
Results: The mean age of the total sample was 38.2 ± 10.6 years. The test-retest reliability of both subscores of the MSIS-29 was excellent
(>0.80). Internal consistency of the MSIS-29 physical and psychological score was 0.968 and 0.914, respectively. Both of the subscores
had excellent internal consistency (>0.80). There was a strong relationship between MSIS-29 physical score with MusiQoL, EQ-5D-3L
(index), EQ-5D-3L (VAS), and BDS scores (p < 0.01, r > 0.50). MSIS-29 physical was moderately related to EDSS (p < 0.01, r = 0.381).
MSIS-29 psychological score was strongly correlated with MusiQoL, EQ-5D-3L (index), EQ-5D-3L (VAS), and BDS scores (p < 0.01, r
> 0.50). On the other hand, there was a weak correlation between MSIS-29 psychological score and EDSS (p < 0.01, r = 0.300).
Conclusion: Turkish version of the MSIS-29 is a reliable and valid tool in individuals with MS.
Key words: MSIS-29, sypmtom severity, patient reported outcomes, psychometrics

1. Introduction
Multiple Sclerosis (MS) negatively affects individuals’
physical/psychological functions and health-related quality
of life [1]. The health-related quality of life of individuals
with MS is lower than individuals with other chronic
diseases [2,3]. In addition to the treatments developed for
MS and related conditions, clinical evaluation methods
that reveal the effects of MS on individuals in daily life
and community-based rehabilitation methods are needed
[4]. The Expanded Disability Status Scale (EDSS) [5] and
Multiple Sclerosis Functional Composite (MSFC) [6]
are primarily preferred in the assessment of disability in
patients with MS. However, among the evaluation methods,
patient-reported outcomes (PROs) are used to evaluate the
individual’s health status with MS from the individual’s
perspective owing to their direct answers [7, 8]. PROs show
the effect of the disease on the individual more broadly [4].

Questionnaires could be performed in any environment
quickly and easily [9]. PROs include symptoms, daily
living activities, quality of life, patient satisfaction and
compliance to reveal the patient’s comprehensive clinical
status [10,11]. An appropriate PRO can detect changes in
the ability of an individual with MS to perform activities
of daily living [12]. There are MS-specific and non-MSspecific PROs used in individuals with MS [13]. Among
those specific to MS, SymptomScreen [14] points out
MS symptoms, Multiple Sclerosis International Quality
of Life (MusiQoL) exposes the health-related quality of
life [15], and Multiple Sclerosis Impact Scale-29 (MSIS29) represents the physical and psychological quality
of life [16]. It was found that MSIS-29 was valid and
reliable on hospital-based samples (MS patients receiving
corticosteroids, MS patients during rehabilitation, and
also primary progressive MS patients) and was identical
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to community samples [17]. The physical subdimension of
MSIS-29 is one of the first scales [16] developed explicitly
for MS, and has also been shown to be correlated with the
commonly used EDSS, MSFC, and Guy’s Neurological
Disability Scale (GNDS) [18]. Validity and reliability
studies of MSIS-29 were conducted in English (original
version) [17], Norwegian [19], Polish [20], Korean [21],
Finnish [4], and Croatian [22]. The present research aimed
to cross-culturally adapt the Multiple Sclerosis Impact
Scale-29 (MSIS-29) into Turkish and evaluate its reliability
and validity in patients with MS.
2. Materials and methods
2.1. Translation and adaptation process
The original MSIS-29 developer granted the authorization
for the translation, adaptation, reliability, and validity
analysis of the Turkish MSIS-29. The common procedures
of Beaton et al. and Guillemin et al. were used for the
translation and adaptation stages [23, 24]. The Turkish
version of the MSIS-29 is presented in Appendix 1.
2.2. Sample size estimation
The sample size of the research was conducted with the
expected Cronbach’s alpha (H1) of approximately 0.80
(based on the original development study and other
versions), the minimum acceptable Cronbach’s alpha
(H0) of 0.70, the significance level of 0.05, power of 0.80,
number of items of the MSIS-29, and 15% drop-out rate.
Accordingly, it was determined that at least 119 cases
should be evaluated to carry out the study [25]. On the
other hand, in calculating test-retest reliability, 0.60 for
minimum acceptable reliability (ICC0), 0.85 for expected
reliability (ICC1), significance level of 0.05, power of
0.80, 2 repetitions per subject (k), and 15% drop-out rate
were considered [26]. Finally, 31 cases were decided to
be sufficient for the reproducibility analysis. As a result,
119 individuals for the first test and 36 for the retest were
enrolled in the research.
2.3. Study design
A psychometric analysis study was conducted at Ege
University, Neurology Department. One hundred nineteen
individuals with MS were enrolled in the study. The study
protocol was approved by the ethics committee of Ege
University (No: 21-5T/97). Mc Donald criteria were used
for the diagnosis of MS. Turkish-speaking patients over 18
years old were included in the study. Exclusion criteria of
the research were; (1) no relapse history for one month,
(2) EDSS score > 7.5 (2), being bedridden (3), other
conditions that alter mobility and function, (4) cognitive
impairments.
Since our study included cultural adaptation, demographic
and socio-cultural characteristics of the patients were
recorded. Then, the physical and individual characteristics
of the participants were documented. Our patients were

evaluated twice at a one-week interval due to the test-retest
reliability study method. In the initial assessment, patients
completed the Multiple Sclerosis Impact Scale-29 (MSIS29) [16], The Multiple Sclerosis International Quality of
Life (MusiQoL) [27], EuroQol-5D-3L (EQ-5D-3L) [28],
and Beck Depression Scale (BDS) [29], respectively. The
clinical neurologist evaluated the patients and fulfilled the
Expanded Disability Status Scale (EDSS) [5] scores. In the
second evaluation conducted one week later, 36 randomly
selected MS patients filled MSIS-29 again. Standardized,
reliable, and valid Turkish versions of all questionnaires
were used.
Multiple Sclerosis Impact Scale-29 (MSIS-29)
Developed by Hobart et al. in 2001 [16]. The tool
includes a 20-statements containing the physical parameters
related to MS disease and a 9-item covering psychological
problems. The physical part includes items 1 to 20. The
psychological part is ranged from items 21 to 29. Participants
are asked to respond to each item regarding the condition’s
impact on their daily life in the last two weeks [30]. The
patients select the answer that strongly represents their
status and responds on a 5-point Likert scale for every item.
The patient’s scores on the two subscales could be summed
and converted to a measure between 0 to 100. High scores
show a high disease impact [22].
The Multiple Sclerosis International Quality of Life
(MusiQoL)
Validity and reliability studies of MusiQoL scales in the
Turkish population were conducted by Idiman et al. [15].
EuroQol-5D-3L (EQ-5D-3L)
EQ-5D-3L includes two subscales: the quality-based
index system and the visual analog scale (VAS). Turkish
validation has been demonstrated [28].
Beck Depression Scale (BDS)
Kapci et al. carried out a reliability and validity study
of the Turkish BDS. This tool represents the depression
severity of the patients [29].
Expanded Disability Status Scale (EDSS)
Kurtzke developed EDSS in 1983 to evaluate disability,
and it is widely used to evaluate MS patients. EDSS score is
calculated by evaluating pyramidal, brainstem, cerebellar,
visual, and sensory systems, and the intestinal-bladder and
mental functions [5].
2.4. Statistical analysis
Statistical analysis was calculated with SPSS for Windows
v25.0 (SPSS Inc, Chicago, IL, USA) software. The mean
and standard deviation were presented for the quantitative
variables. Percentage distribution is presented for
qualitative data. The homogeneity of the participants was
calculated with the Shapiro-Wilk test. The confidence
interval (CI) for Intraclass Correlation Coefficient (ICC)
and correlational analysis was accepted as 0.95.
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2.4.1. Reliability
Two main analyzes were performed for reliability. Firstly,
Cronbach’s alpha value was calculated for each item of
the questionnaire and the total score in order to evaluate
whether the 29 items of MSIS-29 were consistent with
each other. A score of alpha values >0.80 was considered
excellent for internal consistency [31]. Secondly, testretest reliability was evaluated. For the reproducibility
of the MSIS-29, the similarity between the two separate
assessments one week apart was observed with the
Intraclass Correlation Coefficient (ICC, 95% CI). This
measurement investigated whether the Turkish version of
MSIS-29 gave similar results in different measurements.
The Shrout-Fleiss (2,1) type ICC model was preferred. An
ICC value above 0.80 is considered perfectly reliable [32].
2.4.2. Validity
Construct validity of MSIS-29 was evaluated with
Spearman or Pearson correlation coefficient regarding
the normal distribution of the relevant parameter. MSIS29 was compared with MusiQoL, EQ-5D-3L, and BDS.
High correlation indicates high construct validity under
convergent validity. If the r-value > 0.5, the validity was
interpreted as strong. 0.35 < r > 0.50 was considered
moderate and weak if the value <0.35 [33].
3. Results
A total of 119 individuals with MS (91 women, 27 men)
were enrolled in the research. The mean age of the total
sample was 38.2 ± 10.6 years. A vast majority of the

patients were educated in a university or higher degree
(64.6%). The mean MS disease duration of the individuals
was 15.5 ± 3.8 years. The other individual characteristics of
the patients related to cross-cultural adaptation are given
in Table 1. In addition, the mean scores of the clinical
assessments are presented in Table 2. The patients did
not report any difficulties with the Turkish version of the
MSIS-29 in terms of comprehensibility.
3.1. Reliability
The test-retest reliability of both subscores of the MSIS29 was excellent. The ICC score of the MSIS-29 physical
subscale and MSIS-29 phycological subscale was 0.938 (CI:
0.87–0.96) and 0.939 (CI: 0.88–0.96), respectively. Internal
consistency of the MSIS-29 physical and psychological
score was 0.968 and 0.914, respectively. Both of the
subscores had excellent internal consistency. Besides, all
items’ alpha value was excellent (>0.80) (Table 3).
3.2. Validity
There was a strong relationship between MSIS-29 physical
score with MusiQoL, EQ-5D-3L (index), EQ-5D-3L (VAS),
and BDS scores (p < 0.01, r > 0.50). MSIS-29 physical was
moderately related to EDSS (p < 0.01, r = 0.381). MSIS29 psychological score was strongly correlated with
MusiQoL, EQ-5D-3L (index), EQ-5D-3L (VAS), and BDS
scores (p < 0.01, r > 0.50). On the other hand, there was
a weak correlation between MSIS-29 psychological score
and EDSS (p < 0.01, r = 0.300) (Table 4).

Table 1. The participants’ individual characteristics.
n: 119
Age (years, mean ± SD)
BMI
Gender (n, %)
Women
Men
Duration of MS condition (years, mean ± SD)
Education status (n, %)
Elementary school
Secondary school
Senior high school
Bachelors or postgraduate
Marital status (n, %)
Married
Single
Employment (n, %)
Yes
No

Total
38.2 ± 10.6
24.0 ± 3.8
91 (76.5)
27 (23.5)
15.5 ± 3.8
14 (11.8)
4 (3.4)
24 (20.2)
77 (64.6)
75 (63.0)
44 (37.0)
53 (44.5)
66 (55.5)

SD: standard deviation, n: number of patients, BMI: body mass index
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Table 2. Mean scores of the assessments.
n: 119
EDSS
MSIS-29 (physical)
MSIS-29 (psychological)
MusiQoL
EQ-5D-3L (index)
EQ-5D-3L (VAS)
BDS

Mean±SD
1.7 ± 1.4
22.4 ± 21.2
32.7 ± 22.7
44.8 ± 12.9
0.7 ± 0.1
75.6 ± 18.3
10.8 ± 8.6

Range
(0–7.5)
(0–77.5)
(0–83.3)
(21.9–78.0)
(0.1–1)
(30–100)
(0–34)

SD: standard deviation, n: number of patients
Table 3. The internal consistency and test-retest reliability of the MSIS-29 (physical).

Item 1
Item 2
Item 3
Item 4
Item 5
Item 6
Item 7
Item 8
Item 9
Item 10
Item 11
Item 12
Item 13
Item 14
Item 15
Item 16
Item 17
Item 18
Item 19
Item 20
MSIS-29 (physical)
Item 21
Item 22
Item 23
Item 24
Item 25
Item 26
Item 27
Item 28
Item 29
MSIS-29 (psychological)

Test (Mean ± SD)

Retest (Mean±SD)

ICC (95% CI)

α

2.1 ± 1.0
1.8 ± 1.0
2.1 ± 1.0
1.9 ± 1.0
1.7 ± 1.0
2.0 ± 0.9
2.0 ± 1.0
2.1 ± 1.1
1.8 ± 0.8
1.9 ± 1.1
1.7 ± 1.1
1.4 ± 0.9
1.6 ± 0.9
1.8 ± 1.2
1.6 ± 1.0
1.8 ± 1.1
1.6 ± 1.0
2.1 ± 1.2
1.8 ± 1.1
2.3 ± 1.3
22.4 ± 21.2
2.1 ± 1.0
2.2 ± 1.3
2.4 ± 1.2
2.3 ± 1.0
2.3 ± 1.1
2.5 ± 1.1
2.3 ± 1.1
2.1 ± 1.1
2.1 ± 1.2
32.7 ± 22.7

2.0 ± 0.8
1.7 ± 0.9
2.1 ± 1.0
2.2 ± 1.1
1.8 ± 0.9
2.0 ± 0.8
1.9 ± 0.9
2.1 ± 0.8
1.8 ± 0.8
2.0 ± 0.9
1.6 ± 0.9
1.4 ± 0.7
1.6 ± 0.9
1.9 ± 1.1
1.7 ± 1.0
1.8 ± 1.0
1.5 ± 0.8
2.0 ± 1.1
1.7 ± 0.8
2.1 ± 1.1
22.3 ± 19.4
2.1 ± 1.0
2.0 ± 0.8
2.2 ± 0.9
2.1 ± 0.8
2.0 ± 0.9
2.3 ± 0.9
1.9 ± 0.9
2.0 ± 0.7
2.1 ± 1.0
28.0 ± 17.3

0.593 (0.20–0.79)
0.599 (0.21–0.79)
0.496 (0.01–0.74)
0.717 (0.44–0.85)
0.710 (0.43–0.85)
0.807 (0.62–0.90)
0.869 (0.74–0.93)
0.845 (0.69–0.92)
0.940 (0.88–0.97)
0.854 (0.71–0.92)
0.943 (0.88–0.97)
0.909 (0.82–0.95)
0.948 (0.89–0.97)
0.952 (0.90–0.97)
0.937 (0.87–0.96)
0.975 (0.95–0.98)
0.877 (0.75–0.93)
0.773 (0.55–0.88)
0.855 (0.71–0.92)
0.895 (0.79–0.94)
0.938 (0.87–0.96)
0.711 (0.43–0.85)
0.861 (0.72–0.92)
0.865 (0.73–0.93)
0.871 (0.74–0.93)
0.815 (0.63–0.90)
0.792 (0.59–0.89)
0.881 (0.76–0.94)
0.771 (0.55–0.88)
0.812 (0.63–0.90)
0.939 (0.88–0.96)

0.967
0.968
0.966
0.965
0.966
0.967
0.966
0.966
0.969
0.966
0.965
0.966
0.965
0.965
0.966
0.965
0.966
0.965
0.965
0.968
0.968
0.927
0.905
0.895
0.909
0.894
0.900
0.904
0.902
0.899
0.914

n: number of patients, ICC: intra-class correlation coefficient, CI: confidence interval, α: Cronbach’s alpha
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Table 4. Construct validity of the MSIS-29.
n: 119

MSIS-29 (physical)

MSIS-29 (psychological)

MusiQoL

0.774*

0.853*

EQ-5D-3L (index)

–0.786*

–0.749*

EQ-5D-3L (VAS)

–0.832*

–0.755*

BDS

0.542*

0.717*

EDSS

0.381*

0.300*

*: p < 0.01

4. Discussion
The present study investigated the psychometric properties
of the Turkish version of the MSIS-29. MSIS-29 is one
of the most widely and effectively used questionnaires
in evaluating patients with multiple sclerosis [16,30].
Focusing on both the physiological and psychological
dimensions of the effects of the disease on patients, the
MSIS-29 questionnaire is a comprehensive evaluation PRO.
Since it is comprehended that the questionnaires should
be standardized and adapted for the relevant language,
a Turkish standardized version would significantly
contribute to a clinical evaluation in the rehabilitation
process for individuals living in Turkey and Europe whose
native language is Turkish [34]. MSIS-29 has been used in
the UK’s Web Portal of the “UK MS Register” and proxy
use in another study [35,36]. The psychometric properties
have not been demonstrated for Turkish. According to the
results, the internal consistency of the Turkish MSIS-29
was high, the test-retest reliability was excellent, and the
construct validity was sufficient.
The ICC value of the physical and psychological
subscores of the Turkish version of MSIS-29 was above
0.80. Both subscores were highly reliable. The ICC
value found in the development study (physical: 0.81,
psychological: 0.78) [16], the Korean version (physical:
0.90, psychological: 0.78) [21], the Norwegian version
(physical: 0.92, psychological: 0.85) [19] is largely identical
to the values of our study. In this respect, MSIS-29 can
reliably fulfill the same clinical situation in different
measurements. Our psychological subscore had a higher
ICC value (>0.9) than the other versions. Since the BDS
mean of our sample was as low as about 10, it can be
deduced that the effect of illness related to depression
may be relatively low. Therefore, we concluded that
the neuropsychiatric changes, which did not become a
complicated situation, could be more clearly expressed by
the patients.
The Turkish version of the MSIS-29’s Cronbach’s alpha
value for physical and psychological subscores was excellent
(>0.80). In the development study, Cronbach’s alpha
values in the original development study (physical: 0.96,
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psychological: 0.91) [16], in the Croatian version (physical:
0.95, psychological: 0.93) [22], in the Finnish version
(physical: 0.97, psychological: 0.90) [4], in the Norwegian
version (physical: 0.88, psychological: 0.97) [19], and in the
Korean version (physical: 0.97, psychological: 0.96) [21]
were high. Mostly, alpha values are seen to be above 0.90.
These scores pointed out that physical and psychological
subscores can be evaluated consistently in the relevant
clinical group of individuals. In other words, the 20-item
physical subscale items are consistent with each other,
representing the physical subtotal score, while the 9-item
psychological subscore is consistent with each other to
represent the neuropsychiatric condition.
For construct validity, we used popular and goldstandard questionnaires in the field such as MusiQoL,
EQ-5D-3L (index), EQ-5D-3L (VAS), BDS, and EDSS.
MusiQoL reveals the MS-based quality of life and the
impact of disease symptoms on life, EQ-5D-3L indicates
the general quality of life, BDS shows psychological state,
and EDSS demonstrates the individuals’ disability due
to MS. Turkish MSIS-29 was highly correlated with all
PROs (r > 0.50). However, the physical and psychological
subdimension of the Turkish MSIS-29 was moderately and
lowly correlated with the EDSS (r > 0.35, r < 0.35). EDSS is
a clinician-based objective criterion. Therefore, our EDSS
results were relatively low than other PROs comparisons.
In the development study, correlations with SF-36, EQ5D, FAMS, GHQ-12, Barthel Index were examined (r =
0.05; –0.88) [16]. Similar to our study, there were different
levels of similarity from low to high. In the Croatian
validation study, a correlation coefficient between 0.35 and
0.66 was obtained with DASS-21 [22]. They observed a
lower correlation than the BDS results we used similarly.
The observed correlation coefficient with EDSS, EQ5D, and FSS in the Finnish version ranged from 0.2 to
0.8 [4]. These results confirmed our construct validity.
Finally, the correlation of MSIS-29 with EDSS, FSS, PHQ,
and MusiQoL in the Korean version was examined [21].
Construct validity results of our study showed similarity
with the Korean study, in which a correlation was observed
at levels ranging from –0.01 to 0.87.
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4.1. Limitations
Some limitations of the study should be acknowledged and
explained. First, according to the COSMIN declaration,
responsiveness analysis, which is one of the essential
measurements, was not performed for psychometric
analysis in our study [37]. Because this analysis requires
a method that requires long-term follow-up of patients or
their response to treatment. Second, instead of retesting
the entire sample, 36 people randomly determined by
sample size calculation were retested. We preferred this
pragmatic approach, especially when it was difficult to
reach all patients. However, further studies may perform
the reproducibility analysis with a larger sample.
4.2. Conclusions
The results of our study revealed that the Turkish
version of MSIS-29 was translated with a culturally
appropriate adaptation process. According to the results

of psychometric analysis, the MSIS-29 Turkish version is
a valid, reliable PRO tool. Owing to MSIS-29, clinicians
could specifically assess the disease impact of individuals
with MS, both physiologically and psychologically.
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